nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—ADRB1—dilated cardiomyopathy	0.545	1	CbGaD
Aripiprazole—KCNH2—purkinje fiber—dilated cardiomyopathy	0.0246	0.258	CbGeAlD
Aripiprazole—HTR2B—cardial valve—dilated cardiomyopathy	0.0159	0.167	CbGeAlD
Aripiprazole—KCNH2—endocardium—dilated cardiomyopathy	0.0127	0.133	CbGeAlD
Aripiprazole—HTR7—pulmonary artery—dilated cardiomyopathy	0.00551	0.0578	CbGeAlD
Aripiprazole—HTR7—sympathetic nervous system—dilated cardiomyopathy	0.00536	0.0562	CbGeAlD
Aripiprazole—HTR2A—pulmonary artery—dilated cardiomyopathy	0.00344	0.036	CbGeAlD
Aripiprazole—HTR2A—sympathetic nervous system—dilated cardiomyopathy	0.00334	0.0351	CbGeAlD
Aripiprazole—DRD4—heart—dilated cardiomyopathy	0.00239	0.0251	CbGeAlD
Aripiprazole—H1F0—cardiac ventricle—dilated cardiomyopathy	0.00186	0.0195	CbGeAlD
Aripiprazole—H1F0—myocardium—dilated cardiomyopathy	0.00175	0.0183	CbGeAlD
Aripiprazole—ADRB1—cardiac ventricle—dilated cardiomyopathy	0.0014	0.0147	CbGeAlD
Aripiprazole—ADRB1—myocardium—dilated cardiomyopathy	0.00131	0.0138	CbGeAlD
Aripiprazole—H1F0—heart—dilated cardiomyopathy	0.00122	0.0128	CbGeAlD
Aripiprazole—KCNH2—cardiac ventricle—dilated cardiomyopathy	0.00107	0.0112	CbGeAlD
Aripiprazole—ADRA2C—cardiac ventricle—dilated cardiomyopathy	0.00105	0.011	CbGeAlD
Aripiprazole—H1F0—cardiac atrium—dilated cardiomyopathy	0.00104	0.0109	CbGeAlD
Aripiprazole—KCNH2—myocardium—dilated cardiomyopathy	0.001	0.0105	CbGeAlD
Aripiprazole—ADRA2C—myocardium—dilated cardiomyopathy	0.000991	0.0104	CbGeAlD
Aripiprazole—CHRM2—heart—dilated cardiomyopathy	0.00097	0.0102	CbGeAlD
Aripiprazole—ADRB1—heart—dilated cardiomyopathy	0.000918	0.00963	CbGeAlD
Aripiprazole—HTR2B—heart—dilated cardiomyopathy	0.000879	0.00921	CbGeAlD
Aripiprazole—ADRB1—cardiac atrium—dilated cardiomyopathy	0.000785	0.00823	CbGeAlD
Aripiprazole—HTR7—heart—dilated cardiomyopathy	0.000752	0.00789	CbGeAlD
Aripiprazole—ADRA1A—heart—dilated cardiomyopathy	0.000726	0.00761	CbGeAlD
Aripiprazole—KCNH2—heart—dilated cardiomyopathy	0.000701	0.00735	CbGeAlD
Aripiprazole—ADRA2C—heart—dilated cardiomyopathy	0.000692	0.00725	CbGeAlD
Aripiprazole—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.000633	0.00317	CcSEcCtD
Aripiprazole—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00062	0.00311	CcSEcCtD
Aripiprazole—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.000618	0.00309	CcSEcCtD
Aripiprazole—Thirst—Furosemide—dilated cardiomyopathy	0.000613	0.00307	CcSEcCtD
Aripiprazole—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00061	0.00306	CcSEcCtD
Aripiprazole—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00061	0.00305	CcSEcCtD
Aripiprazole—Neck pain—Lisinopril—dilated cardiomyopathy	0.00061	0.00305	CcSEcCtD
Aripiprazole—Purpura—Furosemide—dilated cardiomyopathy	0.000605	0.00303	CcSEcCtD
Aripiprazole—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.000603	0.00302	CcSEcCtD
Aripiprazole—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.000603	0.00302	CcSEcCtD
Aripiprazole—KCNH2—cardiac atrium—dilated cardiomyopathy	0.000599	0.00629	CbGeAlD
Aripiprazole—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.000599	0.003	CcSEcCtD
Aripiprazole—Lethargy—Furosemide—dilated cardiomyopathy	0.000595	0.00298	CcSEcCtD
Aripiprazole—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.000592	0.00297	CcSEcCtD
Aripiprazole—ADRA2C—cardiac atrium—dilated cardiomyopathy	0.000591	0.0062	CbGeAlD
Aripiprazole—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.000589	0.00295	CcSEcCtD
Aripiprazole—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.000585	0.00293	CcSEcCtD
Aripiprazole—Wheezing—Lisinopril—dilated cardiomyopathy	0.000585	0.00293	CcSEcCtD
Aripiprazole—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.000585	0.00293	CcSEcCtD
Aripiprazole—Salivary hypersecretion—Lisinopril—dilated cardiomyopathy	0.000585	0.00293	CcSEcCtD
Aripiprazole—Malaise—Spironolactone—dilated cardiomyopathy	0.000582	0.00291	CcSEcCtD
Aripiprazole—Cystitis—Lisinopril—dilated cardiomyopathy	0.000582	0.00291	CcSEcCtD
Aripiprazole—Leukopenia—Spironolactone—dilated cardiomyopathy	0.000578	0.00289	CcSEcCtD
Aripiprazole—Fluid retention—Lisinopril—dilated cardiomyopathy	0.000572	0.00287	CcSEcCtD
Aripiprazole—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.000569	0.00285	CcSEcCtD
Aripiprazole—Photophobia—Lisinopril—dilated cardiomyopathy	0.000566	0.00283	CcSEcCtD
Aripiprazole—Neuropathy—Lisinopril—dilated cardiomyopathy	0.000566	0.00283	CcSEcCtD
Aripiprazole—Irritability—Furosemide—dilated cardiomyopathy	0.000556	0.00279	CcSEcCtD
Aripiprazole—Urinary retention—Furosemide—dilated cardiomyopathy	0.000554	0.00278	CcSEcCtD
Aripiprazole—ADRA2A—heart—dilated cardiomyopathy	0.000552	0.00579	CbGeAlD
Aripiprazole—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.000546	0.00274	CcSEcCtD
Aripiprazole—Bladder pain—Lisinopril—dilated cardiomyopathy	0.000545	0.00273	CcSEcCtD
Aripiprazole—Discomfort—Spironolactone—dilated cardiomyopathy	0.000543	0.00272	CcSEcCtD
Aripiprazole—Dehydration—Furosemide—dilated cardiomyopathy	0.000542	0.00272	CcSEcCtD
Aripiprazole—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.000539	0.0027	CcSEcCtD
Aripiprazole—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.000536	0.00269	CcSEcCtD
Aripiprazole—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.000532	0.00267	CcSEcCtD
Aripiprazole—Confusional state—Spironolactone—dilated cardiomyopathy	0.000531	0.00266	CcSEcCtD
Aripiprazole—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.000531	0.00266	CcSEcCtD
Aripiprazole—Hypertonia—Lisinopril—dilated cardiomyopathy	0.000528	0.00265	CcSEcCtD
Aripiprazole—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.000527	0.00264	CcSEcCtD
Aripiprazole—Cramp muscle—Furosemide—dilated cardiomyopathy	0.000525	0.00263	CcSEcCtD
Aripiprazole—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.000516	0.00258	CcSEcCtD
Aripiprazole—Muscular weakness—Furosemide—dilated cardiomyopathy	0.000514	0.00258	CcSEcCtD
Aripiprazole—Abdominal distension—Furosemide—dilated cardiomyopathy	0.000507	0.00254	CcSEcCtD
Aripiprazole—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.000505	0.00253	CcSEcCtD
Aripiprazole—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.000503	0.00252	CcSEcCtD
Aripiprazole—Eosinophilia—Furosemide—dilated cardiomyopathy	0.000499	0.0025	CcSEcCtD
Aripiprazole—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.000498	0.0025	CcSEcCtD
Aripiprazole—Pancreatitis—Furosemide—dilated cardiomyopathy	0.000494	0.00247	CcSEcCtD
Aripiprazole—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.000493	0.00247	CcSEcCtD
Aripiprazole—Eczema—Lisinopril—dilated cardiomyopathy	0.000487	0.00244	CcSEcCtD
Aripiprazole—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.000487	0.00244	CcSEcCtD
Aripiprazole—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.00048	0.00241	CcSEcCtD
Aripiprazole—Injury—Lisinopril—dilated cardiomyopathy	0.000476	0.00238	CcSEcCtD
Aripiprazole—ADRA2A—cardiac atrium—dilated cardiomyopathy	0.000472	0.00495	CbGeAlD
Aripiprazole—Libido decreased—Lisinopril—dilated cardiomyopathy	0.000472	0.00236	CcSEcCtD
Aripiprazole—HTR2A—heart—dilated cardiomyopathy	0.000469	0.00492	CbGeAlD
Aripiprazole—Somnolence—Spironolactone—dilated cardiomyopathy	0.000468	0.00235	CcSEcCtD
Aripiprazole—Pollakiuria—Furosemide—dilated cardiomyopathy	0.000465	0.00233	CcSEcCtD
Aripiprazole—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.000462	0.00231	CcSEcCtD
Aripiprazole—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00046	0.0023	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000455	0.00228	CcSEcCtD
Aripiprazole—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.000454	0.00228	CcSEcCtD
Aripiprazole—Arthritis—Lisinopril—dilated cardiomyopathy	0.00045	0.00225	CcSEcCtD
Aripiprazole—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.000448	0.00225	CcSEcCtD
Aripiprazole—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.000446	0.00224	CcSEcCtD
Aripiprazole—Renal failure—Furosemide—dilated cardiomyopathy	0.000442	0.00221	CcSEcCtD
Aripiprazole—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.000439	0.0022	CcSEcCtD
Aripiprazole—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.000437	0.00219	CcSEcCtD
Aripiprazole—Diplopia—Lisinopril—dilated cardiomyopathy	0.000437	0.00219	CcSEcCtD
Aripiprazole—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.000437	0.00219	CcSEcCtD
Aripiprazole—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.000434	0.00217	CcSEcCtD
Aripiprazole—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.000434	0.00217	CcSEcCtD
Aripiprazole—Sweating—Furosemide—dilated cardiomyopathy	0.000431	0.00216	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.000425	0.00213	CcSEcCtD
Aripiprazole—Face oedema—Lisinopril—dilated cardiomyopathy	0.000422	0.00212	CcSEcCtD
Aripiprazole—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.000419	0.0021	CcSEcCtD
Aripiprazole—Urticaria—Spironolactone—dilated cardiomyopathy	0.000418	0.0021	CcSEcCtD
Aripiprazole—Irritability—Lisinopril—dilated cardiomyopathy	0.000417	0.00209	CcSEcCtD
Aripiprazole—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000416	0.00209	CcSEcCtD
Aripiprazole—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.000416	0.00208	CcSEcCtD
Aripiprazole—Ataxia—Lisinopril—dilated cardiomyopathy	0.000411	0.00206	CcSEcCtD
Aripiprazole—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00041	0.00205	CcSEcCtD
Aripiprazole—Dehydration—Lisinopril—dilated cardiomyopathy	0.000407	0.00204	CcSEcCtD
Aripiprazole—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.000399	0.002	CcSEcCtD
Aripiprazole—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000398	0.00199	CcSEcCtD
Aripiprazole—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000395	0.00198	CcSEcCtD
Aripiprazole—Breast disorder—Lisinopril—dilated cardiomyopathy	0.000395	0.00198	CcSEcCtD
Aripiprazole—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.000394	0.00197	CcSEcCtD
Aripiprazole—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.000391	0.00196	CcSEcCtD
Aripiprazole—Visual impairment—Furosemide—dilated cardiomyopathy	0.000389	0.00195	CcSEcCtD
Aripiprazole—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000388	0.00194	CcSEcCtD
Aripiprazole—Gastritis—Lisinopril—dilated cardiomyopathy	0.000387	0.00194	CcSEcCtD
Aripiprazole—Influenza—Lisinopril—dilated cardiomyopathy	0.000378	0.00189	CcSEcCtD
Aripiprazole—Asthma—Lisinopril—dilated cardiomyopathy	0.000378	0.00189	CcSEcCtD
Aripiprazole—Eye disorder—Furosemide—dilated cardiomyopathy	0.000377	0.00189	CcSEcCtD
Aripiprazole—Tinnitus—Furosemide—dilated cardiomyopathy	0.000376	0.00188	CcSEcCtD
Aripiprazole—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.000374	0.00187	CcSEcCtD
Aripiprazole—Pruritus—Spironolactone—dilated cardiomyopathy	0.000373	0.00187	CcSEcCtD
Aripiprazole—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.000371	0.00186	CcSEcCtD
Aripiprazole—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.000368	0.00184	CcSEcCtD
Aripiprazole—Angiopathy—Furosemide—dilated cardiomyopathy	0.000366	0.00183	CcSEcCtD
Aripiprazole—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000364	0.00182	CcSEcCtD
Aripiprazole—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00036	0.0018	CcSEcCtD
Aripiprazole—Dysuria—Lisinopril—dilated cardiomyopathy	0.000353	0.00177	CcSEcCtD
Aripiprazole—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000353	0.00177	CcSEcCtD
Aripiprazole—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.000351	0.00176	CcSEcCtD
Aripiprazole—Erythema—Furosemide—dilated cardiomyopathy	0.000351	0.00176	CcSEcCtD
Aripiprazole—Malnutrition—Furosemide—dilated cardiomyopathy	0.000351	0.00176	CcSEcCtD
Aripiprazole—Dizziness—Spironolactone—dilated cardiomyopathy	0.000348	0.00174	CcSEcCtD
Aripiprazole—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.000348	0.00174	CcSEcCtD
Aripiprazole—Flatulence—Furosemide—dilated cardiomyopathy	0.000346	0.00173	CcSEcCtD
Aripiprazole—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000345	0.00173	CcSEcCtD
Aripiprazole—Weight increased—Lisinopril—dilated cardiomyopathy	0.000344	0.00172	CcSEcCtD
Aripiprazole—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000344	0.00172	CcSEcCtD
Aripiprazole—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000342	0.00171	CcSEcCtD
Aripiprazole—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.000341	0.00171	CcSEcCtD
Aripiprazole—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000339	0.0017	CcSEcCtD
Aripiprazole—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000338	0.00169	CcSEcCtD
Aripiprazole—Depression—Lisinopril—dilated cardiomyopathy	0.000336	0.00168	CcSEcCtD
Aripiprazole—Vomiting—Spironolactone—dilated cardiomyopathy	0.000335	0.00168	CcSEcCtD
Aripiprazole—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.000332	0.00166	CcSEcCtD
Aripiprazole—Rash—Spironolactone—dilated cardiomyopathy	0.000332	0.00166	CcSEcCtD
Aripiprazole—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000332	0.00166	CcSEcCtD
Aripiprazole—Renal failure—Lisinopril—dilated cardiomyopathy	0.000331	0.00166	CcSEcCtD
Aripiprazole—Vision blurred—Furosemide—dilated cardiomyopathy	0.000331	0.00166	CcSEcCtD
Aripiprazole—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00033	0.00166	CcSEcCtD
Aripiprazole—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00033	0.00166	CcSEcCtD
Aripiprazole—Headache—Spironolactone—dilated cardiomyopathy	0.00033	0.00165	CcSEcCtD
Aripiprazole—Jaundice—Lisinopril—dilated cardiomyopathy	0.000329	0.00165	CcSEcCtD
Aripiprazole—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000328	0.00164	CcSEcCtD
Aripiprazole—Anaemia—Furosemide—dilated cardiomyopathy	0.000324	0.00163	CcSEcCtD
Aripiprazole—Sweating—Lisinopril—dilated cardiomyopathy	0.000323	0.00162	CcSEcCtD
Aripiprazole—Agitation—Furosemide—dilated cardiomyopathy	0.000323	0.00162	CcSEcCtD
Aripiprazole—Haematuria—Lisinopril—dilated cardiomyopathy	0.000321	0.00161	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.000319	0.0016	CcSEcCtD
Aripiprazole—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000318	0.00159	CcSEcCtD
Aripiprazole—Sinusitis—Lisinopril—dilated cardiomyopathy	0.000316	0.00158	CcSEcCtD
Aripiprazole—Vertigo—Furosemide—dilated cardiomyopathy	0.000315	0.00158	CcSEcCtD
Aripiprazole—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.000315	0.00158	CcSEcCtD
Aripiprazole—Leukopenia—Furosemide—dilated cardiomyopathy	0.000314	0.00157	CcSEcCtD
Aripiprazole—Nausea—Spironolactone—dilated cardiomyopathy	0.000313	0.00157	CcSEcCtD
Aripiprazole—Bradycardia—Lisinopril—dilated cardiomyopathy	0.000308	0.00154	CcSEcCtD
Aripiprazole—ABCB1—heart—dilated cardiomyopathy	0.000307	0.00322	CbGeAlD
Aripiprazole—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000303	0.00152	CcSEcCtD
Aripiprazole—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000303	0.00152	CcSEcCtD
Aripiprazole—Hallucination—Lisinopril—dilated cardiomyopathy	0.000301	0.00151	CcSEcCtD
Aripiprazole—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.0003	0.0015	CcSEcCtD
Aripiprazole—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000299	0.0015	CcSEcCtD
Aripiprazole—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000298	0.00149	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000297	0.00149	CcSEcCtD
Aripiprazole—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000297	0.00149	CcSEcCtD
Aripiprazole—Dry mouth—Furosemide—dilated cardiomyopathy	0.000292	0.00146	CcSEcCtD
Aripiprazole—Confusional state—Furosemide—dilated cardiomyopathy	0.000289	0.00145	CcSEcCtD
Aripiprazole—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000287	0.00144	CcSEcCtD
Aripiprazole—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000282	0.00141	CcSEcCtD
Aripiprazole—Shock—Furosemide—dilated cardiomyopathy	0.000282	0.00141	CcSEcCtD
Aripiprazole—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000281	0.00141	CcSEcCtD
Aripiprazole—Flushing—Lisinopril—dilated cardiomyopathy	0.000281	0.00141	CcSEcCtD
Aripiprazole—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000281	0.00141	CcSEcCtD
Aripiprazole—Skin disorder—Furosemide—dilated cardiomyopathy	0.000278	0.00139	CcSEcCtD
Aripiprazole—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000277	0.00139	CcSEcCtD
Aripiprazole—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000275	0.00138	CcSEcCtD
Aripiprazole—Anorexia—Furosemide—dilated cardiomyopathy	0.000273	0.00137	CcSEcCtD
Aripiprazole—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000273	0.00137	CcSEcCtD
Aripiprazole—Chills—Lisinopril—dilated cardiomyopathy	0.000272	0.00136	CcSEcCtD
Aripiprazole—Hypotension—Furosemide—dilated cardiomyopathy	0.000268	0.00134	CcSEcCtD
Aripiprazole—Alopecia—Lisinopril—dilated cardiomyopathy	0.000267	0.00134	CcSEcCtD
Aripiprazole—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000265	0.00133	CcSEcCtD
Aripiprazole—Erythema—Lisinopril—dilated cardiomyopathy	0.000263	0.00132	CcSEcCtD
Aripiprazole—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000263	0.00132	CcSEcCtD
Aripiprazole—Flatulence—Lisinopril—dilated cardiomyopathy	0.00026	0.0013	CcSEcCtD
Aripiprazole—Tension—Lisinopril—dilated cardiomyopathy	0.000258	0.00129	CcSEcCtD
Aripiprazole—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000258	0.00129	CcSEcCtD
Aripiprazole—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000257	0.00129	CcSEcCtD
Aripiprazole—Nervousness—Lisinopril—dilated cardiomyopathy	0.000256	0.00128	CcSEcCtD
Aripiprazole—Back pain—Lisinopril—dilated cardiomyopathy	0.000255	0.00128	CcSEcCtD
Aripiprazole—Somnolence—Furosemide—dilated cardiomyopathy	0.000255	0.00128	CcSEcCtD
Aripiprazole—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000253	0.00127	CcSEcCtD
Aripiprazole—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000249	0.00125	CcSEcCtD
Aripiprazole—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000248	0.00124	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000247	0.00124	CcSEcCtD
Aripiprazole—Fatigue—Furosemide—dilated cardiomyopathy	0.000247	0.00124	CcSEcCtD
Aripiprazole—Tremor—Lisinopril—dilated cardiomyopathy	0.000247	0.00124	CcSEcCtD
Aripiprazole—Constipation—Furosemide—dilated cardiomyopathy	0.000245	0.00123	CcSEcCtD
Aripiprazole—Pain—Furosemide—dilated cardiomyopathy	0.000245	0.00123	CcSEcCtD
Aripiprazole—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.000244	0.00122	CcSEcCtD
Aripiprazole—Anaemia—Lisinopril—dilated cardiomyopathy	0.000243	0.00122	CcSEcCtD
Aripiprazole—Angioedema—Lisinopril—dilated cardiomyopathy	0.000241	0.00121	CcSEcCtD
Aripiprazole—Malaise—Lisinopril—dilated cardiomyopathy	0.000238	0.00119	CcSEcCtD
Aripiprazole—Vertigo—Lisinopril—dilated cardiomyopathy	0.000237	0.00119	CcSEcCtD
Aripiprazole—Syncope—Lisinopril—dilated cardiomyopathy	0.000236	0.00118	CcSEcCtD
Aripiprazole—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000236	0.00118	CcSEcCtD
Aripiprazole—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000236	0.00118	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000234	0.00117	CcSEcCtD
Aripiprazole—Palpitations—Lisinopril—dilated cardiomyopathy	0.000233	0.00117	CcSEcCtD
Aripiprazole—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000232	0.00116	CcSEcCtD
Aripiprazole—Cough—Lisinopril—dilated cardiomyopathy	0.00023	0.00115	CcSEcCtD
Aripiprazole—Urticaria—Furosemide—dilated cardiomyopathy	0.000228	0.00114	CcSEcCtD
Aripiprazole—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000226	0.00113	CcSEcCtD
Aripiprazole—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000226	0.00113	CcSEcCtD
Aripiprazole—Myalgia—Lisinopril—dilated cardiomyopathy	0.000224	0.00112	CcSEcCtD
Aripiprazole—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000224	0.00112	CcSEcCtD
Aripiprazole—Chest pain—Lisinopril—dilated cardiomyopathy	0.000224	0.00112	CcSEcCtD
Aripiprazole—Anxiety—Lisinopril—dilated cardiomyopathy	0.000223	0.00112	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000223	0.00112	CcSEcCtD
Aripiprazole—Discomfort—Lisinopril—dilated cardiomyopathy	0.000222	0.00111	CcSEcCtD
Aripiprazole—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000219	0.0011	CcSEcCtD
Aripiprazole—Confusional state—Lisinopril—dilated cardiomyopathy	0.000217	0.00109	CcSEcCtD
Aripiprazole—Oedema—Lisinopril—dilated cardiomyopathy	0.000215	0.00108	CcSEcCtD
Aripiprazole—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000215	0.00108	CcSEcCtD
Aripiprazole—Infection—Lisinopril—dilated cardiomyopathy	0.000214	0.00107	CcSEcCtD
Aripiprazole—Shock—Lisinopril—dilated cardiomyopathy	0.000212	0.00106	CcSEcCtD
Aripiprazole—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000211	0.00106	CcSEcCtD
Aripiprazole—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00021	0.00105	CcSEcCtD
Aripiprazole—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00021	0.00105	CcSEcCtD
Aripiprazole—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000209	0.00105	CcSEcCtD
Aripiprazole—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000208	0.00104	CcSEcCtD
Aripiprazole—Asthenia—Furosemide—dilated cardiomyopathy	0.000206	0.00103	CcSEcCtD
Aripiprazole—Anorexia—Lisinopril—dilated cardiomyopathy	0.000205	0.00103	CcSEcCtD
Aripiprazole—Pruritus—Furosemide—dilated cardiomyopathy	0.000203	0.00102	CcSEcCtD
Aripiprazole—Hypotension—Lisinopril—dilated cardiomyopathy	0.000201	0.00101	CcSEcCtD
Aripiprazole—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000196	0.000982	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000196	0.000981	CcSEcCtD
Aripiprazole—Insomnia—Lisinopril—dilated cardiomyopathy	0.000194	0.000974	CcSEcCtD
Aripiprazole—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000193	0.000967	CcSEcCtD
Aripiprazole—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000192	0.00096	CcSEcCtD
Aripiprazole—Somnolence—Lisinopril—dilated cardiomyopathy	0.000191	0.000957	CcSEcCtD
Aripiprazole—Dizziness—Furosemide—dilated cardiomyopathy	0.000189	0.000949	CcSEcCtD
Aripiprazole—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000189	0.000948	CcSEcCtD
Aripiprazole—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000187	0.000936	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000186	0.00093	CcSEcCtD
Aripiprazole—Fatigue—Lisinopril—dilated cardiomyopathy	0.000185	0.000928	CcSEcCtD
Aripiprazole—Constipation—Lisinopril—dilated cardiomyopathy	0.000184	0.000921	CcSEcCtD
Aripiprazole—Pain—Lisinopril—dilated cardiomyopathy	0.000184	0.000921	CcSEcCtD
Aripiprazole—Vomiting—Furosemide—dilated cardiomyopathy	0.000182	0.000913	CcSEcCtD
Aripiprazole—Rash—Furosemide—dilated cardiomyopathy	0.000181	0.000905	CcSEcCtD
Aripiprazole—Dermatitis—Furosemide—dilated cardiomyopathy	0.00018	0.000904	CcSEcCtD
Aripiprazole—Headache—Furosemide—dilated cardiomyopathy	0.000179	0.000899	CcSEcCtD
Aripiprazole—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000177	0.000887	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000176	0.000881	CcSEcCtD
Aripiprazole—Urticaria—Lisinopril—dilated cardiomyopathy	0.000171	0.000855	CcSEcCtD
Aripiprazole—Nausea—Furosemide—dilated cardiomyopathy	0.00017	0.000852	CcSEcCtD
Aripiprazole—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00017	0.000851	CcSEcCtD
Aripiprazole—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00017	0.000851	CcSEcCtD
Aripiprazole—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000158	0.000793	CcSEcCtD
Aripiprazole—Asthenia—Lisinopril—dilated cardiomyopathy	0.000154	0.000773	CcSEcCtD
Aripiprazole—Pruritus—Lisinopril—dilated cardiomyopathy	0.000152	0.000762	CcSEcCtD
Aripiprazole—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000147	0.000737	CcSEcCtD
Aripiprazole—Dizziness—Lisinopril—dilated cardiomyopathy	0.000142	0.000712	CcSEcCtD
Aripiprazole—Vomiting—Lisinopril—dilated cardiomyopathy	0.000137	0.000685	CcSEcCtD
Aripiprazole—Rash—Lisinopril—dilated cardiomyopathy	0.000136	0.000679	CcSEcCtD
Aripiprazole—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000135	0.000678	CcSEcCtD
Aripiprazole—Headache—Lisinopril—dilated cardiomyopathy	0.000135	0.000675	CcSEcCtD
Aripiprazole—Nausea—Lisinopril—dilated cardiomyopathy	0.000128	0.00064	CcSEcCtD
Aripiprazole—HTR1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.46e-05	9.15e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.46e-05	9.13e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—RAC1—dilated cardiomyopathy	1.46e-05	9.13e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.45e-05	9.07e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—RAC1—dilated cardiomyopathy	1.44e-05	9.04e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	1.44e-05	9.01e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.44e-05	9e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.44e-05	9e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—AGT—dilated cardiomyopathy	1.43e-05	8.94e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.43e-05	8.93e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.43e-05	8.93e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.42e-05	8.91e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.42e-05	8.88e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.42e-05	8.88e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.42e-05	8.85e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.41e-05	8.85e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	1.41e-05	8.81e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—AGT—dilated cardiomyopathy	1.41e-05	8.79e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.4e-05	8.79e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—AGT—dilated cardiomyopathy	1.4e-05	8.78e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.4e-05	8.76e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—AGT—dilated cardiomyopathy	1.4e-05	8.75e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.4e-05	8.74e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.4e-05	8.73e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.4e-05	8.73e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—AGT—dilated cardiomyopathy	1.39e-05	8.72e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.39e-05	8.71e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.38e-05	8.64e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—AGT—dilated cardiomyopathy	1.38e-05	8.64e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.38e-05	8.63e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.38e-05	8.62e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—AGT—dilated cardiomyopathy	1.38e-05	8.61e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.37e-05	8.6e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.37e-05	8.59e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.37e-05	8.57e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.37e-05	8.55e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—RAC1—dilated cardiomyopathy	1.36e-05	8.5e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.36e-05	8.5e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.36e-05	8.5e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—RAC1—dilated cardiomyopathy	1.36e-05	8.49e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.36e-05	8.49e-05	CbGpPWpGaD
Aripiprazole—DRD5—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.36e-05	8.48e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.35e-05	8.48e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.35e-05	8.46e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—RAC1—dilated cardiomyopathy	1.35e-05	8.44e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.34e-05	8.4e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	1.34e-05	8.37e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.32e-05	8.27e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—RAC1—dilated cardiomyopathy	1.32e-05	8.26e-05	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—RAF1—dilated cardiomyopathy	1.32e-05	8.25e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.31e-05	8.22e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—GPX1—dilated cardiomyopathy	1.31e-05	8.17e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.3e-05	8.14e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—RAC1—dilated cardiomyopathy	1.3e-05	8.13e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—AGT—dilated cardiomyopathy	1.3e-05	8.12e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.3e-05	8.12e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—AGT—dilated cardiomyopathy	1.3e-05	8.12e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.3e-05	8.11e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.3e-05	8.11e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.3e-05	8.1e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.29e-05	8.07e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—AGT—dilated cardiomyopathy	1.29e-05	8.06e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—RAC1—dilated cardiomyopathy	1.28e-05	8.02e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—AGT—dilated cardiomyopathy	1.28e-05	8e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.28e-05	7.99e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—CD36—dilated cardiomyopathy	1.27e-05	7.96e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—GPX1—dilated cardiomyopathy	1.27e-05	7.94e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—AGT—dilated cardiomyopathy	1.26e-05	7.89e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.26e-05	7.86e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.25e-05	7.85e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—AGT—dilated cardiomyopathy	1.24e-05	7.77e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—RAC1—dilated cardiomyopathy	1.24e-05	7.76e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—CD36—dilated cardiomyopathy	1.24e-05	7.73e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.23e-05	7.72e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—RAC1—dilated cardiomyopathy	1.23e-05	7.68e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—AGT—dilated cardiomyopathy	1.23e-05	7.66e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.2e-05	7.5e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—AGT—dilated cardiomyopathy	1.19e-05	7.42e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.18e-05	7.39e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.18e-05	7.38e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.18e-05	7.37e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.17e-05	7.34e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—AGT—dilated cardiomyopathy	1.17e-05	7.34e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.17e-05	7.32e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—RAC1—dilated cardiomyopathy	1.17e-05	7.32e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.17e-05	7.32e-05	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—RAF1—dilated cardiomyopathy	1.17e-05	7.3e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.16e-05	7.28e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.16e-05	7.25e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.16e-05	7.23e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—RAC1—dilated cardiomyopathy	1.15e-05	7.22e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.15e-05	7.22e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—AGT—dilated cardiomyopathy	1.15e-05	7.17e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.14e-05	7.12e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.13e-05	7.06e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.12e-05	7.03e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—GPX1—dilated cardiomyopathy	1.12e-05	7.03e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.12e-05	7e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—AGT—dilated cardiomyopathy	1.12e-05	6.99e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.12e-05	6.99e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.11e-05	6.97e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.11e-05	6.97e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—AGT—dilated cardiomyopathy	1.11e-05	6.96e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.11e-05	6.94e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.11e-05	6.93e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—AGT—dilated cardiomyopathy	1.1e-05	6.9e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.1e-05	6.88e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.1e-05	6.86e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—CD36—dilated cardiomyopathy	1.09e-05	6.84e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.09e-05	6.84e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.08e-05	6.74e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.08e-05	6.73e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.07e-05	6.72e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.06e-05	6.63e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—RAC1—dilated cardiomyopathy	1.05e-05	6.58e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.05e-05	6.55e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.05e-05	6.54e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—RAC1—dilated cardiomyopathy	1.04e-05	6.52e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.04e-05	6.5e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—GPX1—dilated cardiomyopathy	1.03e-05	6.45e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.02e-05	6.37e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.02e-05	6.36e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—RAC1—dilated cardiomyopathy	1.01e-05	6.29e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—AGT—dilated cardiomyopathy	1.01e-05	6.29e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—CD36—dilated cardiomyopathy	1e-05	6.28e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—RAC1—dilated cardiomyopathy	1e-05	6.26e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling by GPCR—EGFR—dilated cardiomyopathy	1e-05	6.26e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—AGT—dilated cardiomyopathy	9.96e-06	6.23e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.92e-06	6.2e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling by GPCR—EGFR—dilated cardiomyopathy	9.87e-06	6.17e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—AGT—dilated cardiomyopathy	9.85e-06	6.16e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.78e-06	6.12e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.76e-06	6.1e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—RAC1—dilated cardiomyopathy	9.74e-06	6.09e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.74e-06	6.09e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.7e-06	6.07e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.67e-06	6.05e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.62e-06	6.02e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—AGT—dilated cardiomyopathy	9.61e-06	6.01e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.6e-06	6.01e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—RAC1—dilated cardiomyopathy	9.58e-06	5.99e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.58e-06	5.99e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.57e-06	5.99e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—AGT—dilated cardiomyopathy	9.56e-06	5.98e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.55e-06	5.98e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling by GPCR—EGFR—dilated cardiomyopathy	9.55e-06	5.97e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.54e-06	5.97e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling by GPCR—EGFR—dilated cardiomyopathy	9.45e-06	5.91e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.45e-06	5.91e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	9.44e-06	5.91e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.42e-06	5.89e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—AGT—dilated cardiomyopathy	9.3e-06	5.82e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	9.26e-06	5.79e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	9.2e-06	5.75e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—AGT—dilated cardiomyopathy	9.16e-06	5.73e-05	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—EGFR—dilated cardiomyopathy	9.05e-06	5.66e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—AGT—dilated cardiomyopathy	9.04e-06	5.65e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—RAF1—dilated cardiomyopathy	9.01e-06	5.64e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling by GPCR—EGFR—dilated cardiomyopathy	9.01e-06	5.63e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—RAF1—dilated cardiomyopathy	9e-06	5.63e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—RAF1—dilated cardiomyopathy	8.94e-06	5.6e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling by GPCR—EGFR—dilated cardiomyopathy	8.89e-06	5.56e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	8.88e-06	5.55e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—RAC1—dilated cardiomyopathy	8.83e-06	5.53e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—RAF1—dilated cardiomyopathy	8.76e-06	5.48e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	8.75e-06	5.48e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—RAC1—dilated cardiomyopathy	8.69e-06	5.44e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—RAC1—dilated cardiomyopathy	8.67e-06	5.43e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—RAC1—dilated cardiomyopathy	8.65e-06	5.41e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—RAC1—dilated cardiomyopathy	8.62e-06	5.39e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—RAF1—dilated cardiomyopathy	8.62e-06	5.39e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—RAC1—dilated cardiomyopathy	8.53e-06	5.34e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—RAC1—dilated cardiomyopathy	8.51e-06	5.32e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—RAF1—dilated cardiomyopathy	8.5e-06	5.32e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—AGT—dilated cardiomyopathy	8.44e-06	5.28e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—AGT—dilated cardiomyopathy	8.31e-06	5.2e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—AGT—dilated cardiomyopathy	8.29e-06	5.18e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	8.28e-06	5.18e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—AGT—dilated cardiomyopathy	8.26e-06	5.17e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—AGT—dilated cardiomyopathy	8.23e-06	5.15e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—RAF1—dilated cardiomyopathy	8.23e-06	5.15e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—AGT—dilated cardiomyopathy	8.15e-06	5.1e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—RAF1—dilated cardiomyopathy	8.14e-06	5.09e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—AGT—dilated cardiomyopathy	8.13e-06	5.09e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling by GPCR—EGFR—dilated cardiomyopathy	8.1e-06	5.07e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling by GPCR—EGFR—dilated cardiomyopathy	8.02e-06	5.02e-05	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—EGFR—dilated cardiomyopathy	8.01e-06	5.01e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—RAC1—dilated cardiomyopathy	7.91e-06	4.95e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—RAF1—dilated cardiomyopathy	7.76e-06	4.85e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	7.74e-06	4.84e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—EGFR—dilated cardiomyopathy	7.7e-06	4.82e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—RAF1—dilated cardiomyopathy	7.66e-06	4.79e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—AGT—dilated cardiomyopathy	7.56e-06	4.73e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—EGFR—dilated cardiomyopathy	7.49e-06	4.69e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	7.38e-06	4.61e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	7.13e-06	4.46e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—RAF1—dilated cardiomyopathy	6.97e-06	4.36e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—CD36—dilated cardiomyopathy	6.94e-06	4.34e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—RAF1—dilated cardiomyopathy	6.91e-06	4.32e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.8e-06	4.25e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	6.71e-06	4.2e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.69e-06	4.19e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.68e-06	4.18e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—RAF1—dilated cardiomyopathy	6.67e-06	4.17e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.65e-06	4.16e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—RAF1—dilated cardiomyopathy	6.64e-06	4.15e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.63e-06	4.15e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.57e-06	4.11e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.55e-06	4.1e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	6.54e-06	4.09e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—RAF1—dilated cardiomyopathy	6.46e-06	4.04e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—RAF1—dilated cardiomyopathy	6.35e-06	3.97e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—AGT—dilated cardiomyopathy	6.25e-06	3.91e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—EGFR—dilated cardiomyopathy	6.18e-06	3.87e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—EGFR—dilated cardiomyopathy	6.17e-06	3.86e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—EGFR—dilated cardiomyopathy	6.13e-06	3.84e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.09e-06	3.81e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—EGFR—dilated cardiomyopathy	6.01e-06	3.76e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—EGFR—dilated cardiomyopathy	5.91e-06	3.7e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	5.89e-06	3.68e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—RAF1—dilated cardiomyopathy	5.86e-06	3.66e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—EGFR—dilated cardiomyopathy	5.83e-06	3.65e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—RAF1—dilated cardiomyopathy	5.76e-06	3.61e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—RAF1—dilated cardiomyopathy	5.75e-06	3.6e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—RAF1—dilated cardiomyopathy	5.73e-06	3.59e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—RAF1—dilated cardiomyopathy	5.71e-06	3.57e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—RAF1—dilated cardiomyopathy	5.66e-06	3.54e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—RAF1—dilated cardiomyopathy	5.64e-06	3.53e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—EGFR—dilated cardiomyopathy	5.64e-06	3.53e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—EGFR—dilated cardiomyopathy	5.58e-06	3.49e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—EGFR—dilated cardiomyopathy	5.32e-06	3.33e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—EGFR—dilated cardiomyopathy	5.25e-06	3.28e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—RAF1—dilated cardiomyopathy	5.24e-06	3.28e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—EGFR—dilated cardiomyopathy	4.78e-06	2.99e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—EGFR—dilated cardiomyopathy	4.74e-06	2.96e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—EGFR—dilated cardiomyopathy	4.58e-06	2.86e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—EGFR—dilated cardiomyopathy	4.55e-06	2.85e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—EGFR—dilated cardiomyopathy	4.43e-06	2.77e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	4.39e-06	2.75e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—EGFR—dilated cardiomyopathy	4.36e-06	2.73e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	4.28e-06	2.67e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—EGFR—dilated cardiomyopathy	4.02e-06	2.51e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—EGFR—dilated cardiomyopathy	3.95e-06	2.47e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—EGFR—dilated cardiomyopathy	3.94e-06	2.47e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—EGFR—dilated cardiomyopathy	3.93e-06	2.46e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—EGFR—dilated cardiomyopathy	3.92e-06	2.45e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—EGFR—dilated cardiomyopathy	3.88e-06	2.43e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—EGFR—dilated cardiomyopathy	3.87e-06	2.42e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	3.85e-06	2.41e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—EGFR—dilated cardiomyopathy	3.6e-06	2.25e-05	CbGpPWpGaD
